康希诺(06185.HK)逆弹4.5%曾高见238元 重组新冠疫苗获军队特需药品批件
康希诺生物(06185.HK)公布重组新冠疫苗获军队特需药品批件,该股今早逆市曾涨逾8%高见238元,创逾一个月高遇压,曾回顺至222.8元,现造229.8元,逆升4.5%,成交55万股。
康希诺公布,公司与军事科学院军事医学研究院生物工程研究所联合开发的重组新型冠状病毒疫苗Ad5-nCoV,已於6月25日获得中央军委後勤保障部卫生局颁发的军队特需药品批件,有效期一年。Ad5-nCoV的I期及II期临床试验已在内地开展,总体试验结果表明,Ad5-nCoV具有预防由SARS-CoV-2引起的疾病潜力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.